A clearer vision: insights into juvenile idiopathic arthritis-associated uveitis.

Autor:	M Bani Khalaf I; Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan., Jain H; Department of Medicine, All India Institute of Medical Sciences, Jodhpur, India., Vora NM; Department of Medicine, Terna Speciality Hospital and Research Centre, Navi Mumbai, India., Ul Ain N; Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan., Murtaza F; Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan., Ram MD; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan., Nankani A; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan., Motwani J; Department of Medicine, Liaquat National Hospital and Medical College, Karachi, Pakistan.
Jazyk:	angličtina
Zdroj:	Proceedings (Baylor University. Medical Center) [Proc (Bayl Univ Med Cent)] 2024 Feb 08; Vol. 37 (2), pp. 303-311. Date of Electronic Publication: 2024 Feb 08 (Print Publication: 2024).
DOI:	10.1080/08998280.2024.2305567
Abstrakt:	The aim of this narrative review is to synthesize existing evidence-based knowledge on juvenile idiopathic arthritis-associated uveitis (JIA-U). We highlight epidemiology, pathophysiology, causes and genetics, risk factors, clinical features, diagnosis and screening, laboratory biomarkers, treatment options, trials with recent advances, and research challenges pertaining to JIA-U. The prevalence of JIA-U varies with different JIA subtypes, most frequently associated with the oligoarticular subtype. The risk factors involved in the development of JIA-U include younger age, antinuclear antibody (ANA) positivity, and the oligoarticular subtype of JIA, along with some specific major histocompatibility complex genes. Certain laboratory biomarkers, such as ANA, rheumatoid factor, interferon-λ, erythrocyte sedimentation rate, and transthyretin, have been used in JIA-U diagnosis, progress monitoring, and prognostication. Clinical features of JIA-U can range from asymptomatic to ophthalmic symptoms like redness, blurred vision, decreased visual acuity, hypopyon, and posterior uveitis, which can lead to retinal detachment and macular edema. The management protocol involves topical and systemic steroids, cycloplegics, disease-modifying antirheumatic drugs, biologic drugs, and surgical options. Early detection combined with prompt treatment is crucial to preventing irreversible vision loss in JIA-U. Competing Interests: The authors report no external funding or conflicts of interest. (Copyright © 2024 Baylor University Medical Center.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu